
South African President Cyril Ramaphosa launched a nearly $200 billion investment drive aimed at accelerating economic recovery and industrialization in the face of growing worry over the impact of the Iran war on the continent’s biggest economy.
For more than a decade, South Africa’s economy has barely grown, leaving it with crumbling infrastructure and the need to create jobs in a country where one in three people are unemployed. Ramaphosa’s pitch to investors in Johannesburg this week was that South Africa has fixed the worst bottlenecks: He said the country is opening key sectors to private capital and is ready for large scale investments.
Ramaphosa said the effort will run through 2030 with delegates at the South African Investment Conference pledging $53 billion across 31 projects spanning energy, logistics, manufacturing, and digital infrastructure. They include Coca-Cola’s $1 billion expansion plan, and a $3.6 billion commitment from Sasol — the world’s biggest maker of fuel from coal — to upgrade operations.
LATEST POSTS
- 1
Step by step instructions to Integrate Lab Precious stones into Special Adornments Pieces - 2
Scientists uncover an ant assassination scheme that helps a parasitic queen rise to power - 3
I traveled to 13 countries in 2025. This small island nation surprised me the most. - 4
What are parents to do as doctors clash with Trump administration over vaccines? - 5
What is IDF's view on pontential long-term occupation of southern Lebanon?
Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
Pentagon advances Golden Dome missile defense with new Space Force contracts
As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
The Best 15 Applications for Efficiency and Association
Choosing Moving Styles for Your Restroom Redesign
This Week In Space podcast: Episode 187 — An Inspired Enterprise
Journey through Pages: A Survey of \Plunging into Scholarly Universes\
Pleasant Cycle Courses All over the Planet
Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas













